Although access has improved following the inclusion of anti-HER2 therapies in public health services, the results from our subgroup analysis of HER2-enriched early breast cancer (EBC) patients who did not receive anti-HER2 treatment might not be generalizable to current populations who have access to these therapies. Here, ERBB2 is linked to breast cancer.